BioSpace News Archive

Apobiologix, a division of Apotex Inc., today launched its first oncology therapeutic treatment nationally. The company, a pioneer and leader in oncology biosimilars in Canada, launched Bambevi® (bevacizumab), which is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology announced today that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting.

Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors.

Vektor Medical, Inc. announced U.S. Food and Drug Administration 510 clearance for its novel computational ECG mapping system, vMap™.

Researchers will describe how they used a transporter-competent SCHH model to investigate the DDI potential of bempedoic acid, a drug indicated for hypercholesterolemia.

Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its third quarter ended September 30, 2021.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming virtual investment conferences.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing STS101 nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, reported financial results for the third quarter of 2021 and provided a corporate update.

Treace Medical Concepts, Inc. announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, beginning at approximately 9:20 am ET.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it is advancing HB-201 to Phase 2, to be evaluated in combination with pembrolizumab as 1st- or 2nd-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).